Zomedica Corp. (OTC:ZOMDF) Sees Large Decline in Short Interest

Key Points

• Zomedica Corp. experienced a 34.0% decrease in short interest, dropping from 267,700 shares in August to 176,700 shares by September 15th.
• The company’s stock traded down to $0.07 on Monday, with a market capitalization of $65.85 million and a 50-day moving average of $0.06.
• Zomedica focuses on veterinary health, developing the TRUFORMA platform for diagnostic products and PulseVet for treating musculoskeletal issues in animals.

Zomedica Corp. (OTC:ZOMDF - ) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totaling 176,700 shares, a drop of 34.0% from the August 31st total of 267,700 shares. Based on an average daily volume of 10,007,200 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 10,007,200 shares, the short-interest ratio is currently 0.0 days.

Zomedica Price Performance

ZOMDF stock traded down $0.01 during trading on Monday, hitting $0.07. 4,399,799 shares of the company traded hands, compared to its average volume of 3,765,532. The firm has a market capitalization of $65.85 million, a price-to-earnings ratio of -0.67 and a beta of 1.97. Zomedica has a 1 year low of $0.02 and a 1 year high of $0.16. The stock has a 50-day moving average of $0.06.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.